Cure Pharmaceutical Enters Into Product Development Agreement with Therapix Biosciences To Develop Cannabinoid-Based Product ...
November 07 2017 - 9:00AM
Cure Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive
drug delivery technology announced today that it has entered into a
product development agreement with Therapix Biosciences Ltd.
(Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage
pharmaceutical company focusing on the development of
cannabinoid-based treatments. The joint effort will formulate a
proprietary cannabinoid-based product on CURE’s patented,
multilayer oral thin film (OTF), CureFilm™, for the treatment of a
wide range of sleep disorders.
This agreement is an extension of the recently announced
partnership between CURE, Therapix and Israel’s Assuta Medical
Centers, Ltd. to develop first-in-class therapeutic products in the
fields of personalized medicine and cannabinoids.
Under terms of the product development agreement, CURE will
develop a formulation that combines 2.5mg of dronabinol, a
synthetic form of the key therapeutic cannabinoid endogenous to
cannabis, 9-tetrahydrocannabinol (THC), and 200mg of
palmitoylethanolamide (PEA) on its OTF technology. This formulation
constitutes the advancement of Therapix’s clinical development
program focusing on sleep disorders, as recently announced in the
agreement between Therapix and Assuta Medical Center in the
initiation of a Phase IIa clinical trial in obstructive sleep
apnea.
Sleep apnea is a very large, underserved market with no
available pharmaceutical treatments. An estimated 18 million
patients suffer from this disorder in the U.S. The most common
method of treatment uses a medical device called constant positive
airway pressure (CPAP). While CPAP therapy can be effective in
reducing sleep apnea, about half of patients on CPAP are
non-adherent. This suggests a clear market need for a safe,
effective pharmaceutical treatment for sleep apnea and other sleep
disorders.
“We are enthusiastic about this next phase in our strategic
partnership with Therapix. This product development agreement
serves as testament that we are delivering on the goal we set forth
when we first partnered in July to pool our expertise and resources
to develop new products,” said CEO of CURE Rob Davidson. “Our main
goal at CURE is to improve people’s lives by redefining how
medications are delivered, and sleep disorders is a medical
indication with high unmet need that I think we can significantly
impact.”
Repurposing the FDA-approved dronabinol using Therapix’s
proprietary combination that exhibits the “entourage effect” is key
to improving patient compliance and reducing unwanted side-effects.
Dr. Ascher Shmulewitz, Executive Chairman of Therapix, added, “Our
goal at Therapix is to provide an optimized therapy for the
treatment of a host of unmet medical needs, including sleep
disorders, while reducing the dependence on more harmful
drugs."
Cure Pharmaceuticals has already completed the feasibility study
for this new product and will begin proof of concept in the coming
weeks, with the overall goal of providing a deeper un-interrupted
sleep for the 40 million people who suffer from sleep related
disorders in the United States. This, in addition to the way CURE’s
CureFilm™ OTF technology offers a better option for the 40% of
Americans who can’t swallow pills, improved bioavailability and
fewer side effects, demonstrates CURE’s commitment to creating a
world in which all people can take their medications easily and
effectively.
About CURE Pharmaceutical CURE Pharmaceutical
is a fully integrated life science company committed to improving
drug efficacy, safety and the patient experience through its
proprietary drug dosage forms and delivery systems. CURE has an
industry leading full service cGMP manufacturing facility and is a
preeminent developer and manufacturer of a patented and proprietary
delivery system (CureFilm™), the most advanced oral thin film on
the market today. CURE has developed an array of products in
cutting-edge delivery platforms and partners with leading
pharmaceutical companies. CURE has positioned itself to advance
numerous therapeutic categories, including the pharmaceutical
cannabis sector with partnerships in the U.S., Canada, Israel and
Germany, among other markets. The Company’s mission is to improve
people’s lives by redefining how medicines are delivered and
experienced.
For more information about CURE Pharmaceutical, please visit its
website at www.curepharmaceutical.com.
About Therapix
Biosciences:Therapix Biosciences Ltd. is a specialty
clinical-stage pharmaceutical company led by an experienced team of
senior executives and scientists. Our focus is creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the company is
currently engaged in two internal drug development programs based
on repurposing an FDA approved synthetic cannabinoid
(dronabinol): THX-110 targets the treatment of the symptoms
of Tourette Syndrome; and THX-130 targets the high-value and
under-served market of mild cognitive impairments and Traumatic
Brain Injury (TBI). Please visit our website for more information
at www.therapixbio.com.
Forward-looking statementThis press release
contains forward-looking statements, which are subject to risks and
uncertainties. All statements, other than statements of fact,
including those statements with respect to the Company's business
development, are forward-looking statements. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. We undertake no obligation to publicly update
or revise any forward-looking statements.
CURE Public Relations Contact:
Andrew Hard Chief Executive Officer CMW Media
andrew.hard@cmwmedia.com P. +1888 829-0070
www.cmwmedia.com Therapix Investor
Contact:Josh Blacher Chief Financial Officer Therapix
Biosciences josh@therapixbio.comP. +972-3-616-7055
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Sep 2023 to Sep 2024